1. Maraviroc contributes to the restoration of the homeostasis of regulatory T-cell subsets in antiretroviral-naive HIV-infected subjects 
M.M. Pozo-Balado, I. Rosado-Sánchez, G. Méndez-Lagares, M.M. Rodríguez-Méndez, E. Ruiz-Mateos, M.R. Benhnia, M.A. Muñoz- Fernández, M. Leal, Y.M. Pacheco 
Clinical Microbiology and Infection 
Volume 22, Issue 5, Pages 461.e1-461.e5 (May 2016)
DOI: /j.cmi
Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

2. Fig. 1
(a) Changes in naive regulatory T (nTreg) cell, effector Treg (eTreg) cell and non-Treg cell frequency after the initiation of treatment. The beginning of treatment resulted in a rapid reduction in the frequency of all the FoxP3-expressing cells only in the maraviroc group; no changes were observed in the combined antiretroviral therapy (cART) group at any short time-point. The Wilcoxon tests for longitudinal comparisons are shown and p <0.05 are highlighted in bold. (b) Changes in nTreg, eTreg and non-Treg cells after 48 weeks of successful treatment in the maraviroc and cART groups. In both groups, the frequency of eTreg and non-Treg at baseline was significantly higher than in age-matched healthy participants. After 48 weeks of treatment, eTreg and non-Treg frequencies were restored to healthy levels only in the maraviroc group. Continuous lines indicate the Mann–Whitney U-tests, and dashed lines indicate the Wilcoxon tests. p <0.05 are highlighted in bold.
Clinical Microbiology and Infection  , 461.e1-461.e5DOI: ( /j.cmi )
Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

3. Fig. 2
Correlations between CD4 counts and absolute numbers of naive regulatory T (nTreg) cells, effector Treg (eTreg) cells and non-Treg cells with CD4 T-cell counts at day 0, day 8 and day 30 were performed in maraviroc (a) and combined antiretroviral therapy (ART) (b) groups. The correlations were evaluated using a Spearman rank correlation coefficient test.
Clinical Microbiology and Infection  , 461.e1-461.e5DOI: ( /j.cmi )
Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

4. Fig. S1
Representative dot plot showing gating strategy for FoxP3-expressing subsets. The different FOXP3+ subsets (nTreg, eTreg and non-Treg) were analysed following the differential expression of CD45RA and Foxp3 staining (proposed by Miyara et al. [1]).
Clinical Microbiology and Infection  , 461.e1-461.e5DOI: ( /j.cmi )
Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions

5. Fig. S2
Effect of maraviroc on nTreg (a), eTreg (b) and non-Treg (c) and their respective frequencies in CD4 T-cells (d–f). Isolated peripheral blood mononuclear cells (PBMCs) from eight antiretroviral-naive HIV participants were treated with maraviroc at 1, 10 and 100 μM and cultured for 72 hours. The nTreg, eTreg, non-Treg and CD4 T cell frequencies were assessed by flow cytometry. A significant dose-dependent reduction of eTreg and non-Treg cells was observed, whereas their CD4 T-cell frequency remained invariable. The cell survival was assessed by the Trypan blue exclusion dye test (>85% in all the conditions).
Clinical Microbiology and Infection  , 461.e1-461.e5DOI: ( /j.cmi )
Copyright © 2016 European Society of Clinical Microbiology and Infectious Diseases Terms and Conditions